WuXi STA, a global Contract Research, Development, and Manufacturing Organization (CRDMO), has added two 2,000 L reactors and a large-scale continuous purification system for peptide manufacturing at its Changzhou campus.
 
The new additions expand capability and capacity of WuXi TIDES, a CRDMO platform for oligonucleotide, peptide, and related synthetic conjugates (TIDES drugs). TIDES drug development provides all discovery, CMC development, and the manufacturing supply chain under one roof.
 
With the two new 2,000 L reactors in operation, the total reactor volume of the Solid Phase Peptide Synthesizers (SPPS) at WuXi TIDES has increased to over 10,000 L.
 
In addition to the peptide capacity expansion, WuXi TIDES also added a new continuous purification system that features 300-DAC twin columns for continuous purification of kilogram-scale peptide and oligonucleotide. According to the company, the continuous mode enables a purification process with a faster turnaround time and lower solvent consumption, allowing for a more efficient and sustainable peptide and oligonucleotide manufacturing.

Dr. Minzhang Chen, Co-CEO of WuXi AppTec and CEO of WuXi STA, said, “We are pleased to support our global partners in their efforts to develop TIDES therapies for patients in need. We are committed to continuously enhancing our WuXi TIDES CRDMO platform’s capacity and capability to expedite the development and commercialization of more innovative therapies for patients worldwide.”